The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriers

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 506-515

  Jeganathan, Sinthujah ^a   Sanderson, Lisa ^a   Dogruel, Murat ^a   Rodgers, Jean ^b   Croft, Simon ^c   Thomas, Sarah Ann ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; GLYCOPROTEIN P; INDOMETACIN; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CHOROID PLEXUS; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD-BRAIN BARRIER; CHOROID PLEXUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; MICE; MICE, INBRED BALB C; NIFURTIMOX; P-GLYCOPROTEIN; PROTEIN BINDING; SUCROSE; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 78751555083     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.172981     Document Type: Article

References (40)

1. Bacchi CJ, Nathan HC, Clarkson AB Jr, Bienen EJ, Bitonti AJ, McCann PP, and Sjoerdsma A (1987) Effects of the ornithine decarboxylase inhibitors DL-α-difluoromethylornithine and α-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. Am J Trop Med Hyg 36:46-52.
2. Bacchi CJ, Nathan HC, Yarlett N, Goldberg B, McCann PP, Sjoerdsma A, Saric M, and Clarkson AB Jr (1994) Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-α- difluoromethylornithine and standard trypanocides. Antimicrob Agents Chemother 38:563-569.
3. Baliani A, Bueno GJ, Stewart ML, Yardley V, Brun R, Barrett MP, and Gilbert IH (2005) Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. J Med Chem 48:5570-5579.
4. Bisser S, N'Siesi FX, Lejon V, Preux PM, Van Nieuwenhove S, Miaka Mia Bilenge C, and Būscher P (2007) Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 195:322-329. (Pubitemid 46146108)
5. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, and Priotto G (2007) Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1:e64.
6. Clarkson AB Jr, Bienen EJ, Bacchi CJ, McCann PP, Nathan HC, Hutner SH, and Sjoerdsma A (1984) New drug combination for experimental late-stage African trypanosomiasis: DL-α-difluoromethylornithine (DFMO) with suramin. Am J Trop Med Hyg 33:1073-1077.
7. Duhm B, Maul W, Medenwald H, Patzschke K, and Wegner LA (1972) Investigations on the pharmacokinetics of nifurtimox-35 S in the rat and dog. Arzneimittelforschung 22:1617-1624.
8. Garcia-Bournissen F, Altcheh J, Panchaud A, and Ito S (2010) Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis. Arch Dis Child 95:224-228.
9. Gibbs JE and Thomas SA (2002) The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80:392-404.
10. Gibbs JE, Jayabalan P, and Thomas SA (2003) Mechanisms by which 2′,3′-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy. J Neurochem 84:725-734.
11. Gillespie TJ, Konings PN, Merrill BJ, and Davis TP (1992) A specific enzyme assay for aminopeptidase M in rat brain. Life Sci 51:2097-2106.
12. González-Martin G, Thambo S, Paulos C, Vásquez I, and Paredes J (1992) The pharmacokinetics of nifurtimox in chronic renal failure. Eur J Clin Pharmacol 42:671-673.
13. Grab DJ, Nikolskaia O, Kim YV, Lonsdale-Eccles JD, Ito S, Hara T, Fukuma T, Nyarko E, Kim KJ, Stins MF, et al. (2004) African trypanosome interactions with an in vitro model of the human blood-brain barrier. J Parasitol 90:970-979.
14. Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, and Miller DW (1998) Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 243:816-820.
15. Jennings FW and Gray GD (1983) Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol 7:147-154.
16. Jennings FW, Rodgers J, Bradley B, Gettinby G, Kennedy PG, and Murray M (2002) Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen. Parasitol Int 51:381-388. (Pubitemid 35287509)
17. Lee YJ, Kusuhara H, and Sugiyama Y (2005) Lack of contribution of P-glycoprotein (P-gp) to transport via the mouse blood-cerebrospinal fluid barrier. J Health Sci 51:101-105.
18. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
19. Maina N, Maina KJ, Mäser P, and Brun R (2007) Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate. Acta Trop 104:84-90.
20. Milord F, Loko L, Ethier L, Mpia B, and Pépin J (1993) Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 87:473-477.
21. Montalto de Mecca M, Diaz EG, and Castro JA (2002) Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Toxicol Lett 136:1-8.
22. Morita N, Kusuhara H, Sekine T, Endou H, and Sugiyama Y (2001) Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther 298:1179-1184. (Pubitemid 32761937)
23. Mulenga C, Mhlanga JD, Kristensson K, and Robertson B (2001) Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic disease model. Neuropathol Appl Neurobiol 27:77-85.
24. Namangala B, de Baetselier P, Brijs L, Stijlemans B, Noël W, Pays E, Carrington M, and Beschin A (2000) Attenuation of Trypanosoma brucei is associated with reduced immunosuppression and concomitant production of Th2 lymphokines. J Infect Dis 181:1110-1120.
25. Neal RA, van Bueren J, McCoy NG, and Iwobi M (1989) Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg 83:197-198. (Pubitemid 19265563)
26. Nikolskaia OV, de ALA, Kim YV, Lonsdale-Eccles JD, Fukuma T, Scharfstein J, and Grab DJ (2008) Erratum.J Clin Invest 118:1974.
27. Pépin J, Milord F, Meurice F, Ethier L, Loko L, and Mpia B (1992) High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 86:254-256.
28. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, Ghabri S, and Piola P (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 1:e39.
29. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, et al. (2009) Nifurtimox- eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56-64.
30. Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, and Karunakara U (2007) Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 45:1435-1442.
31. Sanderson L, Dogruel M, Rodgers J, Bradley B, and Thomas SA (2008) The bloodbrain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J Neurochem 107:1136-1146.
32. Sanderson L, Dogruel M, Rodgers J, De Koning HP, and Thomas SA (2009) Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol Exp Ther 329:967-977.
33. Sanderson L, Khan A, and Thomas S (2007) Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice. Antimicrob Agents Chemother 51:3136-3146.
34. Schultzberg M, Ambatsis M, Samuelsson EB, Kristensson K, and van Meirvenne N (1988) Spread of Trypanosoma brucei to the nervous system: early attack on circumventricular organs and sensory ganglia. J Neurosci Res 21:56-61.
35. Soontornmalai A, Vlaming ML, and Fritschy JM (2006) Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 138:159-169.
36. Thomas SA, Abbruscato TJ, Hau VS, Gillespie TJ, Zsigo J, Hruby VJ, and Davis TP (1997) Structure-activity relationships of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J Pharmacol Exp Ther 281:817-825.
37. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, and Hagenbuch B (2002) Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta 1564:183-188.
38. Waalkes TP and DeVita VT (1970) The determination of pentamidine (4,4′-diamidinophenoxypentane) in plasma, urine, and tissues. J Lab Clin Med 75:871-878.
39. Woodrow CJ, Abel PM, and Krishna S (2007) Randomized, controlled trial of treatments for second-stage sleeping sickness. J Infect Dis 196:650-651.
40. Yun O, Priotto G, Tong J, Flevaud L, and Chappuis F (2010) NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 4:e720.